Blog Details

Cancer continues to be a prominent cause of mortality globally. In India, over 1 million new cases of cancer are diagnosed every year. With rising cancer incidence, oncology and cancer care have emerged as a key focus area for the Indian pharmaceutical industry.

India is now among the top global producers of affordable generic cancer medicines. The country has many manufacturers focused on making quality oncology drugs available to patients at affordable prices. These companies are also expanding their capabilities and portfolios for novel biologics and targeted therapies.

Domestic consumption of oncology drugs in India crossed $1.2 billion in 2021 and is projected to grow at a CAGR of 12% to reach $2.5 billion by 2026. The export of oncology products from India reached nearly $2.7 billion in 2021, making the country a key global supplier.

India’s capabilities in end-to-end oncology drug manufacturing APIs and formulations, along with process development and testing, position it well to support rising domestic and international demand. Investments in new technologies and a focus on quality are helping Indian firms adhere to global regulatory standards.

The growth of India’s oncology drug manufacturing sector has significantly improved access and affordability of essential cancer medicines. With its expertise and capacities, India is poised to take a larger role in cancer care globally.

Oncology Drug Market in India

The oncology drug market in India was valued at around $1.7 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 12–15% to reach $3.6 billion by 2022. Factors driving growth in the Indian oncology market include:

• Increasing cancer prevalence: The number of cancer cases in India is rising rapidly, with new cases projected to grow from approximately 1.1 million in 2018 to 1.4 million by 2024. The most common cancers in India are breast, cervical, oral, lung, stomach, colorectal and prostate cancer.
• Improving diagnosis: Cancer screening and early diagnosis programs are expanding in India, leading to more patients being diagnosed and treated. The government is promoting screening initiatives across the country.
• Higher spending and access: Overall healthcare spending is increasing in India, driven by rising incomes, greater health awareness, and improved access to cancer drugs through insurance. Government schemes are making cancer drugs more affordable.
• Investments in healthcare infrastructure are also enabling better cancer diagnosis and treatment with advanced technologies. The number of specialized cancer hospitals and oncology centres is rising.
• Supportive regulations: Government policies are playing a key role in the growth of the oncology market by streamlining the approval process for new drugs, providing incentives for manufacturing cancer drugs in India, and instituting price controls.

The expanding oncology market represents a major opportunity for pharmaceutical companies in India. Domestic manufacturers are strengthening their capabilities and product portfolios to tap into the high demand.

Top Oncology Drugs Manufactured in India

India has emerged as a major hub for manufacturing generic oncology drugs that are more affordable versions of patented drugs. Some of the top-selling oncology drugs manufacturers in India include:

• Trastuzumab – A monoclonal antibody used for treating breast and gastric cancer. Trastuzumab biosimilars are manufactured by companies like Biocon, Mylan and Reliance Life Sciences in India.
• Bevacizumab – A monoclonal antibody that prevents the growth of new blood vessels in tumours. Bevacizumab biosimilars are made by Biocon, Intas Pharmaceuticals and other Indian firms.
• Rituximab – This monoclonal antibody targets CD20 antigen on B cells and is used to treat lymphomas. Rituximab biosimilars are produced by Dr. Reddy’s Laboratories, Intas Pharmaceuticals and others.
• Imatinib – A tyrosine kinase inhibitor used for treating chronic myeloid leukaemia and other cancers. Imatinib generics are manufactured by Ellia Cytocare, Natco Pharma, Sun Pharma and other Indian companies.
• Paclitaxel – An anti-microtubule agent used widely for treating breast, ovarian, lung and other cancers. Paclitaxel formulations are made by companies like Khandelwal Laboratories, Fresenius Kabi Oncology, Troikaa Pharmaceuticals etc.
• Docetaxel – A semi-synthetic taxane that inhibits cell division and is used for breast, prostate, gastric, lung and head-neck cancers. Leading manufacturers of docetaxel include Abbott Healthcare, Cadila Healthcare, and Biochem Pharmaceutical.
• Irinotecan – A key drug for treating colorectal and lung cancers. Irinotecan injections are manufactured by Ellia Cytocare, Sun Pharma, Natco Pharma, Khandelwal Laboratories and others.

This list highlights some of the major oncology drugs being manufactured by Indian pharma companies to make cancer treatment more affordable and accessible globally. The capabilities of Indian firms in producing high-quality oncology medications have made the country a premier generic oncology drugs supplier.

Major Indian Oncology Drug Manufacturers

India is home to a thriving pharmaceutical industry with several major companies focused on manufacturing cancer drugs and treatments. Here are profiles of some of the top Indian oncology drug manufacturers:

Ellia Cytocare

• Specializes in oncology and generics 
• 90+ oncology drugs including oral solids, injectables and biologics
• Key drugs: Lenalidomide, Thalidomide, Bortezomib, Sorafenib, Tamoxifen 
• Oncology formulations facility in India with a capacity of 200 million units per year

Sun Pharma

• One of the largest pharmaceutical companies in India and a leader in oncology medicines.
• Manufactures a wide range of cancer medications including chemotherapy, immunotherapy, and targeted drugs
• Major products include docetaxel, erlotinib, lenalidomide, and sorafenib
• Operates speciality oncology manufacturing facilities meeting international standards
• Exports cancer medicines to over 150 countries globally

Dr Reddy’s Laboratories

• Global pharmaceutical company headquartered in India
• Significant presence in the oncology segment with a wide portfolio of generics and biosimilars
• Key cancer drugs include filgrastim, pegfilgrastim, rituximab, and trastuzumab
• Invests heavily in R&D to develop high-quality and affordable oncology medicines
• Manufacturing facilities approved by the US FDA and other major regulatory agencies

Cipla

• Top Indian pharmaceutical company established in 1935
• Supplies a range of cancer medications in domestic and international markets
• Major oncology products include bortezomib, letrozole, imatinib, and temozolomide
• Operates dedicated manufacturing plant for oncology APIs and formulations
• Known for affordable and high-quality medicines for cancer treatment

Natco Pharma

• Specialty pharmaceutical company focused on oncology and other niche therapies
• Manufactures generic injectables, tablets, and capsules for cancer treatments
• Portfolio includes lenalidomide, sorafenib, erlotinib, bortezomib
• The first company to launch generic lenalidomide in India
• WHO-GMP-certified manufacturing facilities meeting international quality standards

Cadila Healthcare (Zydus Cadila)

• One of the top pharmaceutical companies headquartered in India
• Significant presence in oncology with a range of chemotherapy, immunotherapy and biosimilars
• Manufactures generic versions of rituximab, trastuzumab, bevacizumab, pegfilgrastim
• Invested over $75 million in new biologics manufacturing facility for oncology drugs
• Supplies cancer medicines in over 50 countries globally

Manufacturing Facilities and Capabilities

India has emerged as a leading global hub for pharmaceutical manufacturing, including for oncology medications. The country has a sizable number of manufacturing facilities that produce oncology drugs to meet both domestic and international demand.

Major Indian pharmaceutical companies like Ellia Cytocare, Sun Pharma, Dr Reddy’s Laboratories, Cadila Healthcare, Natco Pharma, and Fresenius Kabi have dedicated manufacturing sites for oncology products. These facilities comply with stringent regulatory standards of WHO-GMP, UK MHRA, US FDA, and others.

The manufacturing plants utilize advanced technology and equipment to produce oncology drugs in various dosage forms – tablets, capsules, injectables, ointments, liquids, etc. They have capabilities for specialized manufacturing processes like cytotoxic handling, controlled substance handling, hormonal drug handling, beta-lactam handling, and potent drug handling.

Some key features of oncology drug manufacturing facilities in India:

• High-quality infrastructure for manufacturing APIs and formulations
• Isolated facilities for highly potent compounds
• Classified areas for handling cytotoxic substances
• Advanced HVAC and air handling units with cascade pressurization
• Automated visual inspection systems
• Sophisticated quality control and analytical testing labs
• Secure cold storage and distribution network

Through continuous expansion and technological upgrades, manufacturing facilities in India can effectively cater to the rising global demand for affordable and high-quality oncology medications.

Key Therapeutic Areas and Drugs

• Immunotherapies: Immunotherapy drugs like checkpoint inhibitors have transformed cancer treatment by harnessing the body’s immune system to fight cancer. Drugs like pembrolizumab and nivolumab (checkpoint inhibitors) are being manufactured by several Indian companies.
• Targeted therapies: Unlike traditional chemotherapy which kills all rapidly dividing cells, targeted therapies specifically attack cancer cells by exploiting vulnerabilities in the cancer’s molecular makeup. Some key targeted therapy drugs made in India include trastuzumab (for breast cancer), rituximab (for lymphoma), and imatinib (for leukaemia).
• Cytotoxic chemotherapy: Conventional cytotoxic chemotherapy drugs that kill replicating cancer cells remain a core treatment modality. Major cytotoxic chemo drugs manufactured in India include gemcitabine, paclitaxel, docetaxel, oxaliplatin, irinotecan, and 5-fluorouracil.
• Supportive care: Supportive care drugs help manage pain, nausea, and other side effects of cancer treatment. Ondansetron, granisetron, and dexamethasone are some examples of supportive care drugs made by Indian companies.
• Hormonal therapies: Hormone receptor-positive cancers like breast and prostate cancer can be treated with hormonal drugs like tamoxifen, letrozole (for breast cancer), and leuprolide, goserelin (for prostate cancer) produced in India.

The portfolio of oncology drugs manufactured by Indian companies spans most major drug classes and treatment modalities. With cutting-edge R&D and manufacturing capabilities, Indian pharma companies are emerging as major global suppliers of high-quality, affordable oncology medications.

Generic Oncology Drugs

India has emerged as a leading manufacturer and supplier of generic oncology drugs globally. The country supplies over 20% of global exports of generic cancer medicines. As patents expire on many blockbuster cancer drugs, Indian pharmaceutical companies have launched high-quality and affordable generic versions for domestic and international markets.

Some key factors that have enabled India to become a powerhouse for generic oncology drugs:

• Strong capabilities in reverse engineering and process chemistry to develop generics quickly after patent expiries. This has helped bring down prices substantially.
• Highly-skilled workforce and low-cost labour, make production very cost-competitive.
• Supportive government policies that do not allow patent-term extensions. This has enabled faster generic drug development.
• A large number of USFDA-approved manufacturing facilities meet international quality standards.

Some major generic oncology drugs exported from India include generic versions of imatinib, erlotinib, lenalidomide, sorafenib, sunitinib, bortezomib, everolimus etc. By providing these high-quality and low-cost generics worldwide, Indian drug makers have helped improve access and lower treatment costs for cancer patients globally.

Going forward, India is likely to consolidate its position as a leading supplier of generic oncology drugs, as more biologics and targeted therapies come off patent over the next decade. The country’s scientific skills and capabilities will play a vital role in expanding access to affordable cancer medicines globally.

Research and Development

The oncology drugs market in India is rapidly growing and Indian pharmaceutical companies are increasing their investments in research and development of new drugs and technologies. Some key points:

• Indian companies like Ellia Cytocare, Sun Pharma, Lupin, Dr Reddy’s Laboratories, Cipla, and Biocon have set up dedicated research centres to develop novel formulations and new drug delivery systems for cancer treatment.
• Investments in cutting-edge areas like nanotechnology, targeted therapy, immunotherapy, and biosimilars are on the rise. Biocon leads in biosimilars with its cancer drug formulations.
• Collaboration with global biopharma companies to license patented molecules and co-develop drugs is also gaining steam. Sun Pharma joined hands with AstraZeneca and Merck, while Dr Reddy’s works with Fujifilm and Merck.
• Contract research capabilities are being developed through tie-ups with global CROs to offer services internationally. GVK Bio partners with various companies for oncology clinical trials and bioanalytical services.
• Government schemes like the New Millennium Indian Technology Leadership Initiative provide funds to promote public-private partnerships and high-risk innovative research in oncology.
• Investments in research infrastructure are increasing, with advanced R&D facilities equipped with the latest technologies. Jubilant Biosys expanded its Bangalore R&D center in 2022.
• Focus on indigenous innovation through the in-licensing of promising molecules from Indian academic institutions and integrating medicinal chemistry with genomics and proteomics.
• Building a strong talent pool through industry-academia partnerships. Companies are collaborating with IITs, CSIR, DBT, and other scientific institutions.

The rising investments and strategic initiatives for R&D show the commitment of Indian firms to strengthen their oncology research capabilities and deliver newer, more advanced therapies globally.

Regulations and Approvals

India has a robust regulatory framework for pharmaceuticals and medical devices that ensures the safety, efficacy and quality of anticancer drug manufacturers and exporters in India. The key regulations governing oncology drugs in India are:

• Drugs and Cosmetics Act, 1940 and Rules 1945 – Provides the legal framework for regulating the import, manufacture, distribution and sale of drugs in India. Establishes regulatory authorities like state licensing and the Central Drugs Standard Control Organization (CDSCO).
• New Drugs and Clinical Trials Rules, 2019 – Lays down requirements for clinical trials and marketing authorisation of new drugs in India. Specifies procedures for conducting clinical trials, application for new drug approval, and periodic safety reporting.
• Good Manufacturing Practices – Guidelines for the manufacture, testing, and quality control of drugs. Mandatory GMP certification is required for the production and sale of pharmaceuticals.
• Schedule Y – Describes requirements for clinical trials and submission of clinical trial data for new drug approval. Lays down guidelines for generating evidence of safety and effectiveness.
• Environmental Regulations – Guidelines for disposal of hazardous pharmaceutical waste generated during drug manufacturing. Ensures environmental safety.

The CDSCO is the national regulatory body for pharmaceuticals and medical devices under the Ministry of Health and Family Welfare. It is responsible for approval of new drugs and clinical trials. The CDSCO works closely with the FDA for vetting and approval of oncology drugs following established safety, efficacy and quality standards. Stringent regulatory oversight ensures the high quality of oncology drug manufacturers and suppliers in India.

Future Outlook

The future outlook for the oncology drugs market in India is bright, with significant growth opportunities on the horizon. Some key aspects:

• Market Size Growth: The Indian oncology drugs market is projected to grow at a CAGR of 12% from 2022-2027, reaching nearly $3.6 billion by 2027 according to one estimate. Growing cancer prevalence, improving diagnosis rates, rising incomes and increasing health insurance coverage will drive growth.
• Increasing Affordability: With more competition and launches of biosimilars, prices of cancer drugs are expected to decline, increasing affordability and access for patients. This will open up the market.
• Investments in Manufacturing: Many Indian pharma companies are expanding manufacturing capacities for oncology APIs and formulations given the rising domestic and export demand. This will boost production.
• Export Focus: Indian drug makers are focused on getting USFDA and other approvals for their oncology drugs to tap export markets. Oncology exports are projected to rise steadily.
• Innovation Pipeline: Several Indian companies are bolstering their oncology pipelines through R&D partnerships, acquisitions and in-house research. Novel biologics, antibody-drug conjugates and immunotherapy drugs will augment portfolios.
• Government Support: Government initiatives like tax benefits, clusters for API manufacturing etc aim to encourage domestic manufacturing and innovation in oncology drugs. This will aid growth.
• Rising Cancer Incidence: With risk factors like smoking, unhealthy diets and sedentary lifestyles on the rise, India’s cancer burden is increasing. This expands the patient pool and the need for quality, affordable drugs.

Overall, the oncology drugs market outlook for domestic manufacturers seems robust. With the right strategies and investments, Indian companies can leverage the opportunities for sustainable and profitable growth.

Conclusion: The crucial role of oncology drug manufacturers in driving innovation in India’s research and development sector

As an anticancer drug manufacturer and supplier in India, I am proud to be part of an industry that is driving innovation in the country’s research and development sector. Despite the challenges we face, our relentless pursuit of developing effective and affordable cancer treatments has yielded remarkable results.

Through collaborations with academic institutions, government support, and a focus on research and development, we have achieved breakthroughs that have transformed cancer care. With the future looking promising, I am confident that oncology drug manufacturers will continue to play a crucial role in improving patient outcomes and driving innovation in India’s research and development sector.